Evidence map›Paper›PMID 38951350›Full record

ReviewInternational ophthalmology2024

Publication trends of vascular endothelial growth factor (VEGF) and anti-VEGF treatment in neovascular age-related macular degeneration during 2001-2020: a 20-year bibliometric study.

Jiali Wu, Yimin Wang, Min Zhang, Xiaodong Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Medical hypothesis, discovery & innovation ophthalmology journal · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiali Wu *Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Wujing Road No. 85, Hongkou District, Shanghai, 200080, China.
Yimin Wang *Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China.
Min Zhang *Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Wujing Road No. 85, Hongkou District, Shanghai, 200080, China.
Xiaodong SunDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Wujing Road No. 85, Hongkou District, Shanghai, 200080, China. xdsun@sjtu.edu.cn.

Funding

National Natural Science Foundation of China 82171076Shanghai Sailing Program 22YF1435500
6 · The paper itself

Abstract

purposeThis study sought to provide an overview of the current research and further analyze publication trends in the field of vascular endothelial growth factor (VEGF) and anti-VEGF treatment for neovascular age-related macular degeneration (NVAMD).

methodsWe downloaded all related publications from 2001 to 2020 from the Web of Science Core Collection and conducted a bibliometric analysis using the bibiometrix package in R programming software.

resultsA total of 3717 publications were included in the analysis. The USA contributed the largest number of publications (1443), and achieved the highest number of citations (74,946) and H-index value (28). Johns Hopkins University, USA, was the top institution with the most publications, and Peter A. Campochiaro was the most productive professor at The Wilmer Eye Institute, USA. 9.60% of the total publications were from the Journal of Retinal and Vitreous Diseases. Trend analysis demonstrated that anti-VEGF therapy was introduced in early 2000 after steroids, and the last 2 decades have witnessed the blossom of several anti-VEGF agents. "Treat-and-extend" and "resistance" were two popular trend topics in recent years.

conclusionsThe USA occupies a dominant position in the research field of VEGF and anti-VEGF treatments in NVAMD. Steroid administration, photodynamic therapy, and anti-VEGF therapy have been pivotal advances in the treatment of NVAMD patients over the past 2 decades. Limited acting period and resistance are potential investigation directions in future studies.

Indexed as

Angiogenesis InhibitorsBibliometricsVascular Endothelial Growth Factor AWet Macular DegenerationHumansIntravitreal InjectionsAngiogenesis InhibitorsVascular Endothelial Growth Factor ABibliometric analysisNeovascular age-related macular degenerationResearch trend

Identifiers

PMID38951350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.